Last July, a group of researchers published a Review that highlighted several approaches addressed to overcome chemotype-specific resistance to inhibitors in anticancer treatment. Nowadays, one of the major limiting factors in anticancer therapy is the emergence of the target's resistance to already designed drugs. Targeting multiple binding pockets or allosteric binding sites and designing inhibitors with distinct binding modes are among such strategies. The two next approaches are targeted degradation using PROteolysis Targeting Chimeras (PROTACs) and cysteine-targeting covalent inhibitors.
We at Chemspace offer you sets with Covalent Fragments and Covalent Modifiers!
To browse the sets, please use the following links:
- In-Stock Covalent Fragments - 23 860 compounds
- Covalent Fragments Pre-Plated set - 4 987 compounds
- In-Stock Covalent Modifiers - 200 177 compounds
Expansion of the pre-plated set is available on request!
In case of any questions just drop us a line: email@example.com.